| 08/17/04 - 6:01 p.m. | Eyetech/Pfizer Announce FDA Acceptance of the New Drug Application for Macugen(TM) (pegaptanib sodium injection) | | 07/23/04 - 2:01 p.m. | Eyetech Pharmaceuticals, Inc. Reports Second Quarter 2004 Financial Results | | 07/12/04 - 5:32 p.m. | Eyetech to Announce Second Quarter 2004 Financial Results on July 23, 2004 | | 06/18/04 - 4:31 p.m. | Eyetech Pharmaceuticals, Inc. Announces Appointment of Michael J. Regan to the Board of Directors | | 06/17/04 - 9:16 a.m. | Eyetech/Pfizer File New Drug Application for Macugen(TM) (pegaptanib sodium injection), the First Investigational Anti-VEGF Therapy for Wet Age-Related Macular Degeneration | | 06/15/04 - 5:16 p.m. | Eyetech Pharmaceuticals, Inc. Announces Appointment of Phillip M. Satow to the Board of Directors and Resignation of Michael G. Mullen from the Board | | 06/02/04 - 5:52 p.m. | Eyetech Pharmaceuticals, Inc. Completes Secondary Public Offering | | 06/01/04 - 5:01 p.m. | Eyetech to Present at Goldman Sachs Annual Global Healthcare Conference | | 05/26/04 - 8:26 p.m. | Eyetech Pharmaceuticals, Inc. Announces Secondary Offering | | 05/26/04 - 9:37 a.m. | FDA Announces Advisory Committee Meeting Date for Macugen(TM) (pegaptanib sodium injection) | | 05/13/04 - 7:45 a.m. | Eyetech Pharmaceuticals, Inc. Files Registration Statement | | 05/03/04 - 8:45 p.m. | Macugen(TM) (pegaptanib sodium injection) Shows Positive Visual and Anatomical
Outcomes in a Phase 2 Trial for Patients with Diabetic Macular Edema (DME) | | 05/03/04 - 8:45 p.m. | Eyetech Pharmaceuticals, Inc. Reports First Quarter 2004 Financial Results | | 04/27/04 - 4:30 p.m. | Eyetech to Present at Morgan Stanley's Second Annual Global Healthcare
Unplugged Conference | | 04/14/04 - 6:30 p.m. | Eyetech to Announce First Quarter 2004 Financial Results on May 3, 2004 | | 04/14/04 - 8:00 a.m. | Eyetech and Archemix Announce Collaboration to Discover and Develop
Therapeutic Aptamers for Ophthalmology | | 03/31/04 - 7:20 p.m. | Eyetech Pharmaceuticals' Officers and Directors Adopt 10b5-1 Securities
Trading Plans | | 03/04/04 - 12:00 p.m. | Eyetech to Present at SG Cowen's 24th Annual Health Care Conference | | 03/04/04 - 9:30 a.m. | Eyetech Pharmaceuticals Presents Macugen(TM) (Pegaptanib Sodium) Data at The
Aspen Retinal Detachment Society Meeting in Aspen, Colorado | | 02/23/04 - 8:15 p.m. | Eyetech Pharmaceuticals, Inc. Reports Fourth Quarter and Year End 2003
Financial Results | | 02/17/04 - 1:10 p.m. | Eyetech to Announce 2003 Fourth Quarter and Year-End Results
On February 23, 2004 | | 02/04/04 - 5:22 p.m. | Eyetech Pharmaceuticals, Inc. Completes Initial Public Offering | | 01/29/04 - 11:36 p.m. | Eyetech Pharmaceuticals, Inc. Announces Its Initial Public Offering |
|
The documents contained in this website include forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995) that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included on this web site regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. There are a number of important factors that could cause Eyetech"s actual results to differ materially from those indicated by such forward-looking statements. You should consult our Registration on Form S-1 and our Annual Reports on Form 10-K and subsequent reports filed with the SEC. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date any such statement was first made.
|
|